Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
Vevye Logo Vevye Logo Contact Us

Works Fast To deliver results

VEVYE® shows clinically meaningful and statistically significant improvement in total corneal fluorescein staining (tCFS) by Day 15 in clinical studies.5-6

Works Fast To deliver results

VEVYE® shows clinically meaningful and statistically significant improvement in total corneal fluorescein staining (tCFS) by Day 15 in clinical studies.5-6

Signs

Symptoms

Continued Relief in Dry Eye Disease Symptoms 7

In the open label extension study, VEVYE® (cyclosporine ophthalmic solution) 0.1% demonstrated continuous symptom improvements as measured by the Visual Analog Scale (VAS) for Dryness.

All symptoms measured in the ESSENCE-2 OLE Study showed improvement from baseline.7

22% Improvement

in dryness within 1 month of starting treatment

Discomfort (Dryness)

VAS Scores

In a phase 3 clinical study, subjects that
saw 3 or more grades of improvement in tcfs saw

Statistically significant improvement in 6 out of 8 measured symptoms by Day 29. 7

Patient Symptom Improvements 6-7

In a phase 3, single-arm, open label extension study, responders experienced improvement in VAS symptoms compared to baseline over a 52-week period.

A Phase 3, single-arm, open label extension study.

Back to Signs Data

time to try vevye

Connect with a representative to learn more.

Connect with a representative to learn more.

Contact Us

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.